HER 2 neg: FOLFOX pembro Keynote 859: improved OS 13 months versus 11.5 months with and without pembro. OS, PFS , ORR benefit. Across all PDL1 groups, benefit noted.
HER 2 positive CapeOX with trastuzumab- median OS 17 months. Add pembro to the triplet, OS 20 months if CPS > 1. Keynote 811. There was an OS benefit. Patients with a PD-L1 CPS ≥ 1 experienced a 21% reduction in the risk of death and a 28% reduction in disease progression with pembrolizumab, whereas the CPS < 1 subset (15% of the population) derived no benefit
No comments:
Post a Comment